Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Idronoxil · NV-06

Small molecule · Inhibitor of X-linked inhibitor of apoptosis protein (XIAP) and CASP8 and FADD-like apoptosis regulator (CFLAR) · developed by Kazia Therapeutics

Phase 1 Most advanced trial (none active)
KZIA Developer
1 Registered trials

What is Idronoxil?

Idronoxil is a synthetic flavonoid derivative that activates the mitochondrial caspase system, inhibits XIAP, and disrupts FLIP expression, promoting tumor cell apoptosis. It also stabilizes the cleavable complex of DNA topoisomerase II. It has been studied in unspecified adult solid tumors.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NV-06
Drug type
Small molecule
Targets
X-linked inhibitor of apoptosis protein (XIAP), CASP8 and FADD-like apoptosis regulator (CFLAR), DNA topoisomerase II (TOP2A) (secondary target)
Mechanism
Inhibitor of X-linked inhibitor of apoptosis protein (XIAP) and CASP8 and FADD-like apoptosis regulator (CFLAR)
Pathways
mitochondrial caspase activation, apoptosis, DNA replication
Therapy area
Oncology
Developer
Kazia Therapeutics Limited (KZIA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1
UNII
995FT1W541

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00022295 Phase 1 Unspecified Adult Solid Tumor, Protocol Specific Completed KZIA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Unspecified Adult Solid Tumor, Protocol Specific

Other drugs acting on XIAP / CFLAR

More from Kazia Therapeutics

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KZIA page.

Follow KZIA, the company behind Idronoxil

See KZIA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KZIA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.